OpenEvidence Acquires AI Advertising Startup Amaro
OpenEvidence has acquired Amaro, an AI-native advertising company, announced in a press release. Amaro, backed by Google Ventures and Greycroft, specializes in optimizing advertising deployment through intelligent automation.
The acquisition aims to expand OpenEvidence's platform capabilities, particularly in building a modern advertising infrastructure for healthcare professionals. OpenEvidence, which powers over half a million clinical conversations daily, sees this acquisition as a strategic fit to accelerate its growth and enhance its ad-supported model.
Amaro's team and technology will integrate into OpenEvidence's operations, supporting its mission to provide high-quality information to clinicians. This move follows OpenEvidence's recent $210 million Series B financing, valuing the company at $3.5 billion.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation
The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.
Read more